Great Point Partners’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Great Point Partners’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-799,999	Closed	-$16.1M	–	50
2021 Q3	$16.1M	Buy	+799,999	New	+$22.1M	3.76%	7

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Great Point Partners's DRNA Position: Q4 2021 in Review

Great Point Partners sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 799,999 shares — an estimated $16.1M sold.

Great Point Partners first reported a position in DRNA in Q3 2021 and held it in 1 quarter. The position peaked at $16.1M in Q3 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Great Point Partners reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Great Point Partners sold 799,999 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $16.1M.
Great Point Partners first reported a position in Dicerna Pharmaceuticals, Inc. in Q3 2021 and held it in 1 quarter.
Great Point Partners's Dicerna Pharmaceuticals, Inc. position peaked at $16.1M in Q3 2021.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Great Point Partners's 13F filing for Q4 2021, filed 14 Feb 2022.